Trellus Health PLC Posting of Annual Report and Notice of AGM (7368A)
26 5월 2023 - 3:00PM
UK Regulatory
TIDMTRLS
RNS Number : 7368A
Trellus Health PLC
26 May 2023
Trellus Health plc
("Trellus Health" or the "Company")
Posting of Annual Report & Accounts
and
Notice of Annual General Meeting
LONDON, UK. AND NEW YORK, U.S. (26 May 2023). Trellus Health plc
(AIM: TRLS), which is commercializing a scientifically validated,
personalized resilience-driven self-management solution for chronic
health conditions at their intersection with mental health,
confirms that the Annual Report and Accounts for the year ended 31
December 2022 ("2022 Annual Report") and the Notice of the 2023
Annual General Meeting ("AGM") have now been published on the
Company's website here .
The 2022 Annual Report, the Notice of AGM and details for voting
by proxy will be posted to shareholders today, on 26 May 2023.
The AGM will be held at 12:30pm on 22 June 2023 at 6 Stratton
Street, London, W1J 8LD, and will consider the Resolutions set out
in the Notice of AGM.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the
2023 AGM in the post. Instead, shareholders will be able to vote
electronically using the link www.signalshares.com . Proxy votes
must be received no later than 12:30pm on 20 June 2023.
Shareholders may request a hard copy form of proxy directly from
the Registrars, Link Group, on Tel: 0371 664 0300. Calls are
charged at the standard geographic rate and will vary by provider.
Calls outside the United Kingdom will be charged at the applicable
international rate. Lines are open between 09:00 - 17:30, Monday to
Friday excluding public holidays in England and Wales.
For further information please contact:
Trellus Health plc https://trellushealth.com/
Dr. Marla Dubinsky, CEO and Co-Founder Via Walbrook PR
Dr. Daniel Mahony Chairman
Singer Capital Markets (Nominated Tel: +44 (0)20 7496 3000
Adviser and Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / 0 7748 651 727
Phillip Marriage / 07867 984 082
About Trellus Health plc ( www.trellushealth.com )
Trellus Health (LSE: TRLS) is the first resilience based digital
health company focused on the intersection of chronic illness and
mental health. Trellus Health integrates its proprietary
resilience-based methodology with the technology, tools and team to
deliver a whole-person technology-enhanced experience that results
in relieving disease burden, building self-management skills and
promoting individual health behaviours that enable thriving in the
face of a chronic condition. Through its TrellusElevate(TM)
connected health platform and companion App, the company addresses
both physical and behavioural health together, in context, to
improve outcomes and reduce healthcare costs across the healthcare
ecosystem.
The Company was initially focused on inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis but has now added Irritable Bowel
Syndrome ("IBS"). Given the common struggles of self-management,
Trellus Health considers its approach to have potential utility and
demand across many chronic conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD
treated using the methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12
months following starting the program(2) .
The Company was founded by Mount Sinai faculty members Marla C.
Dubinsky, MD and Laurie Keefer, PhD, both with decades of combined
experience in IBD and psychogastroenterology, respectively. Trellus
Health's patent-pending GRITT(TM) resilience assessment and
personalized resilience training methodology was developed and
validated at the Mount Sinai Health System to build resilience and
wellness for improved outcomes at lower cost.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
1) Source:
https://www.cdc.gov/chronicdisease/about/costs/index.htm )
2) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAAMMTMTJTTTJ
(END) Dow Jones Newswires
May 26, 2023 02:00 ET (06:00 GMT)
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
